Lipocine Inc. Files 8-K Report
Ticker: LPCN · Form: 8-K · Filed: Apr 2, 2026 · CIK: 0001535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: LPCN
TL;DR
Lipocine filed an 8-K, check for updates.
AI Summary
On April 2, 2026, Lipocine Inc. filed an 8-K report detailing other events and financial statements. The filing includes exhibits such as the 8-K form itself and supplementary materials. No specific financial figures or material events were detailed in the provided filing information.
Why It Matters
This filing indicates Lipocine Inc. is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's status or recent developments.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report with no immediate indication of significant negative or positive events.
Key Players & Entities
- Lipocine Inc. (company) — Filer of the 8-K report
- 0001535955 (company) — CIK number for Lipocine Inc.
- 0001493152-26-014834 (other) — SEC Accession Number for the filing
- 2026-04-02 (date) — Filing Date and Period of Report
FAQ
What specific events are detailed in Item 8.01 of the 8-K filing?
The provided filing information lists Item 8.01 as 'Other Events' but does not specify the nature of these events.
What is the purpose of Item 9.01 in this 8-K filing?
Item 9.01 pertains to 'Financial Statements and Exhibits', indicating that financial information and supporting documents are included.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 2, 2026, at 09:35:13.
What is the CIK number for Lipocine Inc.?
The CIK number for Lipocine Inc. is 0001535955.
Where is Lipocine Inc. located based on the mailing address provided?
Lipocine Inc.'s mailing address is 675 Arapaen Drive, Suite 202, Salt Lake City, UT 84108.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2026-04-02 09:35:13
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 36KB
- form8-k_001.jpg (GRAPHIC) — 6KB
- 0001493152-26-014834.txt ( ) — 261KB
- lpcn-20260402.xsd (EX-101.SCH) — 3KB
- lpcn-20260402_lab.xml (EX-101.LAB) — 33KB
- lpcn-20260402_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On April 2, 2026, the Company issued a press release announcing topline safety and efficacy results for LPCN 1154 in patients with postpartum depression. The press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed with this report: Exhibit No. Description 99.1 Press Release announcing Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: April 2, 2026 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer